BACKGROUND/AIM: Published data have shown that palbociclib-fulvestrant can significantly improve the progression-free survival (PFS) of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer patients, but not of Japanese patients. We conducted this retrospective study to verify the efficacy and safety of palbociclib-fulvestrant in Japanese patients. PATIENTS AND METHODS: ER+/HER2- metastatic breast cancer patients treated with fulvestrant (n=39) or palbociclib-fulvestrant (n=31) at the Saitama Medical Center from July 2012 to November 2018 were evaluated. RESULTS: Overall response rates (ORRs) were 2.6% (fulvestrant) and 41.9% (palbociclib-fulvestrant) (p<0.001), and clinical benefit rates (CBRs) were 23.1% and 61.3% (p=0.002), respectively. The palbociclib-fulvestrant group had significantly higher CBR and PFS (hazard ratio(HR):0.272, 95% confidence interval(95CI):0.128-0.574 for PFS). Grade 3/4 neutropenia occurred in 80.6% of the palbociclib-fulvestrant group, while febrile neutropenia was not detected. CONCLUSION: Japanese ER+/HER2- metastatic breast cancer patients tolerated palbociclib-fulvestrant, with significantly improved clinical outcomes. Copyright
BACKGROUND/AIM: Published data have shown that palbociclib-fulvestrant can significantly improve the progression-free survival (PFS) of estrogen receptor-positive/humanepidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancerpatients, but not of Japanese patients. We conducted this retrospective study to verify the efficacy and safety of palbociclib-fulvestrant in Japanese patients. PATIENTS AND METHODS: ER+/HER2- metastatic breast cancerpatients treated with fulvestrant (n=39) or palbociclib-fulvestrant (n=31) at the Saitama Medical Center from July 2012 to November 2018 were evaluated. RESULTS: Overall response rates (ORRs) were 2.6% (fulvestrant) and 41.9% (palbociclib-fulvestrant) (p<0.001), and clinical benefit rates (CBRs) were 23.1% and 61.3% (p=0.002), respectively. The palbociclib-fulvestrant group had significantly higher CBR and PFS (hazard ratio(HR):0.272, 95% confidence interval(95CI):0.128-0.574 for PFS). Grade 3/4 neutropenia occurred in 80.6% of the palbociclib-fulvestrant group, while febrile neutropenia was not detected. CONCLUSION: Japanese ER+/HER2- metastatic breast cancerpatients tolerated palbociclib-fulvestrant, with significantly improved clinical outcomes. Copyright
Authors: John F R Robertson; Igor M Bondarenko; Ekaterina Trishkina; Mikhail Dvorkin; Lawrence Panasci; Alexey Manikhas; Yaroslav Shparyk; Servando Cardona-Huerta; Kwok-Leung Cheung; Manuel Jesus Philco-Salas; Manuel Ruiz-Borrego; Zhimin Shao; Shinzaburo Noguchi; Jacqui Rowbottom; Mary Stuart; Lynda M Grinsted; Mehdi Fazal; Matthew J Ellis Journal: Lancet Date: 2016-11-29 Impact factor: 79.321
Authors: J G Klijn; L V Beex; L Mauriac; J A van Zijl; C Veyret; J Wildiers; J Jassem; M Piccart; J Burghouts; D Becquart; C Seynaeve; F Mignolet; L Duchateau Journal: J Natl Cancer Inst Date: 2000-06-07 Impact factor: 13.506
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Sunil Verma; Cynthia Huang Bartlett; Patrick Schnell; Angela M DeMichele; Sherene Loi; Jungsil Ro; Marco Colleoni; Hiroji Iwata; Nadia Harbeck; Massimo Cristofanilli; Ke Zhang; Alexandra Thiele; Nicholas C Turner; Hope S Rugo Journal: Oncologist Date: 2016-07-01
Authors: S P Myrand; K Sekiguchi; M Z Man; X Lin; R-Y Tzeng; C-H Teng; B Hee; M Garrett; H Kikkawa; C-Y Lin; S M Eddy; J Dostalik; J Mount; J Azuma; Y Fujio; I-J Jang; S-G Shin; M R Bleavins; J A Williams; J D Paulauskis; K D Wilner Journal: Clin Pharmacol Ther Date: 2008-03-19 Impact factor: 6.875